BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 30355918)

  • 1. Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40.
    Yu DS; Weng TH; Shen L; Wu XX; Hu CY; Wang FXC; Wu ZG; Wu HB; Wu NP; Li LJ; Yao H
    Cell Physiol Biochem; 2018; 50(3):1055-1067. PubMed ID: 30355918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 3. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens.
    Shahhosseini S; Das D; Qiu X; Feldmann H; Jones SM; Suresh MR
    J Virol Methods; 2007 Jul; 143(1):29-37. PubMed ID: 17368819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
    Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
    J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
    Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
    J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
    Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry.
    Tran EE; Nelson EA; Bonagiri P; Simmons JA; Shoemaker CJ; Schmaljohn CS; Kobinger GP; Zeitlin L; Subramaniam S; White JM
    J Virol; 2016 Sep; 90(17):7618-27. PubMed ID: 27279622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor.
    Yu JS; Liao HX; Gerdon AE; Huffman B; Scearce RM; McAdams M; Alam SM; Popernack PM; Sullivan NJ; Wright D; Cliffel DE; Nabel GJ; Haynes BF
    J Virol Methods; 2006 Nov; 137(2):219-28. PubMed ID: 16857271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.
    Wec AZ; Bornholdt ZA; He S; Herbert AS; Goodwin E; Wirchnianski AS; Gunn BM; Zhang Z; Zhu W; Liu G; Abelson DM; Moyer CL; Jangra RK; James RM; Bakken RR; Bohorova N; Bohorov O; Kim DH; Pauly MH; Velasco J; Bortz RH; Whaley KJ; Goldstein T; Anthony SJ; Alter G; Walker LM; Dye JM; Zeitlin L; Qiu X; Chandran K
    Cell Host Microbe; 2019 Jan; 25(1):39-48.e5. PubMed ID: 30629917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.
    Wec AZ; Herbert AS; Murin CD; Nyakatura EK; Abelson DM; Fels JM; He S; James RM; de La Vega MA; Zhu W; Bakken RR; Goodwin E; Turner HL; Jangra RK; Zeitlin L; Qiu X; Lai JR; Walker LM; Ward AB; Dye JM; Chandran K; Bornholdt ZA
    Cell; 2017 May; 169(5):878-890.e15. PubMed ID: 28525755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
    Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
    Front Immunol; 2021; 12():706757. PubMed ID: 34335620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.
    Bornholdt ZA; Turner HL; Murin CD; Li W; Sok D; Souders CA; Piper AE; Goff A; Shamblin JD; Wollen SE; Sprague TR; Fusco ML; Pommert KB; Cavacini LA; Smith HL; Klempner M; Reimann KA; Krauland E; Gerngross TU; Wittrup KD; Saphire EO; Burton DR; Glass PJ; Ward AB; Walker LM
    Science; 2016 Mar; 351(6277):1078-83. PubMed ID: 26912366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization.
    Gilchuk P; Murin CD; Milligan JC; Cross RW; Mire CE; Ilinykh PA; Huang K; Kuzmina N; Altman PX; Hui S; Gunn BM; Bryan AL; Davidson E; Doranz BJ; Turner HL; Alkutkar T; Flinko R; Orlandi C; Carnahan R; Nargi R; Bombardi RG; Vodzak ME; Li S; Okoli A; Ibeawuchi M; Ohiaeri B; Lewis GK; Alter G; Bukreyev A; Saphire EO; Geisbert TW; Ward AB; Crowe JE
    Immunity; 2020 Feb; 52(2):388-403.e12. PubMed ID: 32023489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
    Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
    J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.
    Audet J; Wong G; Wang H; Lu G; Gao GF; Kobinger G; Qiu X
    Sci Rep; 2014 Nov; 4():6881. PubMed ID: 25375093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.
    Howell KA; Qiu X; Brannan JM; Bryan C; Davidson E; Holtsberg FW; Wec AZ; Shulenin S; Biggins JE; Douglas R; Enterlein SG; Turner HL; Pallesen J; Murin CD; He S; Kroeker A; Vu H; Herbert AS; Fusco ML; Nyakatura EK; Lai JR; Keck ZY; Foung SKH; Saphire EO; Zeitlin L; Ward AB; Chandran K; Doranz BJ; Kobinger GP; Dye JM; Aman MJ
    Cell Rep; 2016 May; 15(7):1514-1526. PubMed ID: 27160900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
    Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE
    Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus.
    Ayouba A; Touré A; Butel C; Keita AK; Binetruy F; Sow MS; Foulongne V; Delaporte E; Peeters M
    J Clin Microbiol; 2017 Jan; 55(1):165-176. PubMed ID: 27795350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential requirements for FcγR engagement by protective antibodies against Ebola virus.
    Bournazos S; DiLillo DJ; Goff AJ; Glass PJ; Ravetch JV
    Proc Natl Acad Sci U S A; 2019 Oct; 116(40):20054-20062. PubMed ID: 31484758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.